Classes
DEA Class; Rx
Common Brand Names; Capastat
- Antitubercular Agents
Description
Parenteral polypeptide antibiotic, exact mechanism unknown.
Used as a second line agent in combination with other medications for the treatment of pulmonary tuberculosis.
Practical use is limited by routes of administration, adverse effects of nephrotoxicity and neurotoxicity.
Indications
Indicated for treatment of Tuberculosis
Contraindications
Hypersensitivity
Pregnancy
Adverse Effects
- Nephrotoxicity, incr BUN (36%)
- Hearing loss (11% subclinical; 3% clinical)
- Eosinophilia (dose related, >5%)
- Incr LFTs
- Inj site pain/induration
- Leukopenia
- Maculopapular rash
- Urticaria
Warnings
Renal impairment, auditory impairment, history of allergic rxns
Risk of hypokalemia
Risk of rare but potentially fatal toxic nephritis
Pregnancy and Lactation
Pregnancy Category: C
Lactation: excretion in milk unknown; use with caution
Maximum Dosage
1 g/day (20 mg/kg/day) or 5 days/week IV/IM or 25 mg/kg/dose IV/IM 3 days/week.
1 g/day (20 mg/kg/day) or 5 days/week IV/IM or 25 mg/kg/dose IV/IM 3 days/week.
Safety and efficacy have not been established; however, 30 mg/kg/day (Max: 1 g/day), 5 days/week, or twice weekly IV/IM has been used off-label.
Safety and efficacy have not been established; however, 30 mg/kg/day (Max: 1 g/day), 5 days/week, or twice weekly IV/IM has been used off-label.
Safety and efficacy have not been established; however, 30 mg/kg/day, 5 days/week, or twice weekly IV/IM has been used off-label.
Safety and efficacy have not been established; however, 30 mg/kg/day IV/IM has been used off-label.
How supplied
Capreomycin sulfate
powder for injection
- 1g/vial
